{"id":90409,"date":"2019-05-07T16:08:16","date_gmt":"2019-05-07T23:08:16","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2019\/05\/intellia-fixed-95-98-t-cells-inside-the-body-using-crispr-gene-therapy"},"modified":"2019-05-07T16:08:16","modified_gmt":"2019-05-07T23:08:16","slug":"intellia-fixed-95-98-t-cells-inside-the-body-using-crispr-gene-therapy","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2019\/05\/intellia-fixed-95-98-t-cells-inside-the-body-using-crispr-gene-therapy","title":{"rendered":"Intellia Fixed 95\u201398% T-Cells Inside the Body Using CRISPR Gene Therapy"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/intellia-fixed-95-98-t-cells-inside-the-body-using-crispr-gene-therapy2.jpg\"><\/a><\/p>\n<p><a href=\"http:\/\/ir.intelliatx.com\/news-releases\/news-release-details\/intellia-therapeutics-presents-new-vivo-and-engineered-cell\">Intellia and its research collaborator, IRCCS Ospedale San Raffaele<\/a> presented new in vitro data showing that CRISPR\/Cas9 editing resulted in over 98% knockout of the endogenous T cell receptor (TCR), while achieving transfer of various Wilms\u2019 Tumor 1 (WT1)-specific TCRs into over 95% of isolated T cells.<\/p>\n<p>Intellia Therapeutics is a leading genome editing company focused on developing curative therapeutics using the CRISPR\/Cas9 system. Intellia believes the CRISPR\/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course, and through improved cell therapies that can treat cancer and immunological diseases, or can replace patients\u2019 diseased cells.<\/p>\n<p>SOURCES- Intellia Written By <i>Brian Wang<\/i>. <a href=\"http:\/\/Nextbigfuture.com\">Nextbigfuture.com<\/a><\/p>\n<p><a href=\"https:\/\/www.nextbigfuture.com\/2019\/05\/intellia-fixed-95-98-t-cells-inside-the-body-using-crispr-gene-therapy.html\" target=\"_blank\" rel=\"noopener noreferrer\"><\/p>\n<div style=\"clear:both;\">Read more<\/div>\n<p><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Intellia and its research collaborator, IRCCS Ospedale San Raffaele presented new in vitro data showing that CRISPR\/Cas9 editing resulted in over 98% knockout of the endogenous T cell receptor (TCR), while achieving transfer of various Wilms\u2019 Tumor 1 (WT1)-specific TCRs into over 95% of isolated T cells. Intellia Therapeutics is a leading genome editing company [\u2026]<\/p>\n","protected":false},"author":513,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,20],"tags":[],"class_list":["post-90409","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-futurism"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/90409","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/513"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=90409"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/90409\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=90409"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=90409"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=90409"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}